GSK’227 Gets FDA Breakthrough Therapy Designation for Advanced Osteosarcoma
GSK5764227 has been granted FDA breakthrough therapy designation, potentially expediting its development as a treatment for relapsed/refractory osteosarcoma.
Related Articles
Hand therapy interventions for the prevention of chemotherapy-induced peripheral neuropathy of the hands in patients with pancreatic cancer
This trial compared investigational hand therapy intervention with a traditional occupational therapy approach to prevent chemotherapy-induced peripheral n
Reviewing the Options for Bladder Cancer in Different Settings
Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.
Nivolumab Plus Ipilimumab May Offer Efficacious Therapeutic Approach in Rare GU Cancers
Bradley McGregor, MD, discusses the findings from a phase 2 study of nivolumab plus ipilimumab in rare GU cancers.
Using Biopsies to Inform Response Characteristics in Kidney Cancer
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
CDK4/6 Inhibitors, Targeted Therapies May Expand Their Reach in HR+ Metastatic Breast Cancer
Hope S. Rugo, MD, discusses questions regarding CDK4/6 inhibitors and targeted therapies in HR-positive, HER2-negative advanced breast cancer.
Comment on “Stereotactic radiosurgery for patients with spinal metastases from prostate cancer”
Journal of Neuro-Oncology –
Daratumab Added to Standard Frontline AL Amyloidosis Treatment Demonstrates Improved Clinical Outcomes
In the final analysis of the ANDROMEDA study, additional daratumab to standard bortezomib, cyclophosphamide, and dexamethasone therapy demonstrated better hematological responses and clinical improvement for…
A Pragmatist’s View on Biomarker-Driven Decisions in Oncology: Episode 1
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
Study Identifies How Ovarian Cancer Protects Itself, Paves Way for Improved Immunotherapy Approach
Eczema-linked protein helps cancer survive, suggesting potential for skin drug-based treatment.